Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase

Bibliography

• Choo QL, Kuo G, Weiner A, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62
   PubMed Web of Science ®Google Scholar
• WHO. Fact Sheet No. 164: Hepatitis C. October 2000 [cited; Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html]
   Google Scholar
• Sharma P, Lok A. Viral hepatitis and liver transplantation. Semin Liver Dis 2006;26:285-97
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31(3):777-82
   PubMed Web of Science ®Google Scholar
• Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42(4):962-73
   PubMed Web of Science ®Google Scholar
• Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hep 2007;14(Suppl 1):82-8
   PubMed Web of Science ®Google Scholar
• Kronenberger B, Welsch C, Forestier N, Zeuzem S. Novel hepatitis C drugs in current trials. Clin Liver Dis 2008;12(3):529-55
   PubMed Web of Science ®Google Scholar
• Liu-Young G, Kozal MJ. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDs 2008;22(6):449-57
   PubMed Web of Science ®Google Scholar
• Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J Exp Med 2003;197:633-42
   PubMed Web of Science ®Google Scholar
• Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003;100:7271-6
   PubMed Web of Science ®Google Scholar
• Lohmann V, Korner F, Koch JO, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285(5424):110-3
   PubMed Web of Science ®Google Scholar
• Vrolijk JM, Kaul A, Hansen BE, et al. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods 2003;110(2):201-9
   PubMed Web of Science ®Google Scholar
• Lee JC, Yu MC, Lien TW, et al. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors. Assay Drug Dev Technol 2005;3(4):385-92
   PubMed Web of Science ®Google Scholar
• Kakiuchi N, Nishikawa S. High throughput assay of hepatitis C virus NS3 protease inhibitors. Curr Topics Virol 2002;2:161-70
   Google Scholar
• Mao SS, DiMuzio J, McHale C, et al. A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations. Anal Biochem 2008;373(1):1-8
   PubMed Web of Science ®Google Scholar
• Wang YK, Rigat KL, Roberts SB, Gao M. A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase. Anal Biochem 2006;359(1):106-11
   PubMed Web of Science ®Google Scholar
• Lahser FC, Malcolm BA. A continuous nonradioactive assay for RNA-dependent RNA polymerase activity. Anal Biochem 2004;325(2):247-54
   PubMed Web of Science ®Google Scholar
• Trozzi C, Bartholomew L, Ceccacci A, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003;77(6):3669-76
   PubMed Web of Science ®Google Scholar
• Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003;78(49):49164-70
   Google Scholar
• Le Pogam S, Jiang WR, Leveque V, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-Methyl-Cytidine or to R1479 show lack of cross resistance. Virology 2006;351(2):349-59
   PubMed Web of Science ®Google Scholar
• Shi ST, Herlihy KJ, Graham JP, et al. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008;52(2):675-83
   PubMed Web of Science ®Google Scholar
• Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antivir Res 2006;70(2):28-38
   PubMed Web of Science ®Google Scholar
• Robida JM, Nelson HB, Liu Z, Tang H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol 2007;81(11):5829-40
   PubMed Web of Science ®Google Scholar
• Fernandes F, Poole DS, Hoover S, et al. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 2007;46(4):1026-33
   PubMed Web of Science ®Google Scholar
• Yang F, Robotham JM, Nelson HB, et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 2008;82(11):5269-78
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309(5734):623-6
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11(7):791-6
   PubMed Web of Science ®Google Scholar
• Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005;102(26):9294-9
   PubMed Web of Science ®Google Scholar
• Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 2006;103(19):7408-13
   PubMed Web of Science ®Google Scholar
• Kato T, Furusaka A, Miyamoto M, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001;64(3):334-9
   PubMed Web of Science ®Google Scholar
• Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2006;2(2):183-212
   PubMed Web of Science ®Google Scholar
• Welbourn S, Green R, Gamache I, et al. hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication. J Biol Chem 2005;280(33):29604-11
   PubMed Web of Science ®Google Scholar
• Darke PL, Jacobs AR, Waxman L, Kuo LC. Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides. Implications for control of viral processing. J Biol Chem 1999;274(49):34511-4
   PubMed Web of Science ®Google Scholar
• Thibeault D, Maurice R, Pilote L, et al. In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J Biol Chem 2001;276(49):46678-84
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharma. Hepatitis C virus NS2/3 assay by immunodetection of autocleavage products. US2007141701; 2007
   Google Scholar
• Whitney M, Stack JH, Darke PL, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity. J Biomol Screen 2002;7(2):149-54
   PubMed Web of Science ®Google Scholar
• Bayer AG. Method for examining and evaluating virus enzymes in HTS. WO04013349; 2004
   Google Scholar
• Lorenz IC, Marcotrigiano J, Dentzer TG, Rice CM. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 2006;442(7104):831-5
   PubMed Web of Science ®Google Scholar
• Jirasko V, Montserret R, Appel N, et al. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. J Biol Chem 2008;283(42):28546-62
   PubMed Web of Science ®Google Scholar
• Lam AM, Frick DN. Hepatitis C virus subgenomic replicon requires and active NS3 RNA helicase. J Virol 2006;80:404-11
   PubMed Web of Science ®Google Scholar
• Dumont S, Cheng W, Serebrov V, et al. RNA translocation and unwinding mechanism of HCV NS3 helicase and its coordination by ATP. Nature 2006;439(7072):105-8
   PubMed Web of Science ®Google Scholar
• Myong S, Bruno MM, Pyle AM, Ha T. Spring-loaded mechanism of DNA unwinding by hepatitis C virus NS3 helicase. Science 2007;317(5837):513-6
   PubMed Web of Science ®Google Scholar
• Cheng W, Dumont S, Tinoco I, Bustamante C. NS3 helicase actively separates RNA strands and senses sequence barriers ahead of the opening fork. Proc Natl Acad Sci USA 2007;104(35):13954-9, S/1-S/10
   PubMed Web of Science ®Google Scholar
• Kwong AD, Rao BG, Jeang KT. Viral and cellular RNA helicases as antiviral targets. Nat Rev Drug Discov 2005;4:845-53
   PubMed Web of Science ®Google Scholar
• Hicham Alaoui-Ismaili M, Gervais C, Brunette S, et al. A novel high throughput screening assay for HCV NS3 helicase activity. Antivir Res 2000;46(3):181-93
   PubMed Web of Science ®Google Scholar
• Kyono K, Miyashiro M, Taguchi I. Detection of hepatitis C virus helicase activity using the scintillation proximity assay system. Anal Biochem 1998;257:120-6
   PubMed Web of Science ®Google Scholar
• Boguszewska-Chachulska AM, Krawczyk M, Stankiewicz A, et al. Direct fluorometric measurement of hepatitis C virus helicase activity. FEBS Lett 2004;567(2-3):253-8
   PubMed Web of Science ®Google Scholar
• Koch JO, Lohmann V, Herian U, Bartenchlager R. In vitro studies on the activation of hepatitis C virus NS3 proteinase by the NS4A cofactor. Virology 1996;221:54-66
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Pragai BM, Montserret R, et al. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. J Virol 2007;81(17):8905-18
   PubMed Web of Science ®Google Scholar
• Kou YH, Chou SM, Wang YM, et al. Hepatitis C virus NS4A inhibits cap-dependent and the viral IRES-mediated translation through interacting with eukaryotic elongation factor 1A. J Biomed Sci 2006;13(6):861-74
   PubMed Web of Science ®Google Scholar
• Brass V, Berke JM, Montserre R, et al. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci USA 2008;105(38):14545-50
   PubMed Web of Science ®Google Scholar
• Einav S, Gerber D, bryson PD, et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 2008;26(9):1019-27
   PubMed Web of Science ®Google Scholar
• Moradpour D, Gosert R, Egger D, et al. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antivir Res 2003;60(2):103-9
   PubMed Web of Science ®Google Scholar
• Bryson PD, Cho NJ, Einav S, et al. A small Molecule inhibits HCV replication adn inhibits NS4B localization. 15th International Symposium on Hepatitis C Virus and Related Viruses. San Antonio, Texas USA; 2008
   Google Scholar
• Einav S, Elazar M, Danieli T, Glenn JS. A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. J Virol 2004;78(20):11288-95
   PubMed Web of Science ®Google Scholar
• Yu GY, Lee KJ, Gao L, Lai MMC. Palmitoylation and polymerization of hepatitis C virus NS4B protein. J Virol 2006;80(12):6013-23
   PubMed Web of Science ®Google Scholar
• Lundin M, Lindstroem H, Groenwall C, Persson MAA. Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. J Gen Virol 2006;87(11):3263-72
   PubMed Web of Science ®Google Scholar
• MacDonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004;85(9):2485-502
   PubMed Web of Science ®Google Scholar
• Schmitz U, Tan SL. NS5A - from obscurity to new target for HCV therapy. Recent Patents Anti-Infect Drug Discov 2008;3(2):77-92
   PubMedGoogle Scholar
• Penin F, Brass V, Appel N, et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 2004;279(39):40835-43
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005;435(7040):374-9
   PubMed Web of Science ®Google Scholar
• Merck. Hepatitis C virus replication inhibitors targeting NS4A binding site of NS2/3 protease. WO01016379; 2001
   Google Scholar
• Waxman L, Whitney M, Pollok BA, et al. Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci USA 2001;98(24):13931-5
   PubMed Web of Science ®Google Scholar
• Viropharma, Inc. Compounds, compositions and methods for treatment of hepatitis C. US5633388; 1997
   Google Scholar
• Viropharma, Inc. Compounds, compositions and methods for treatment of hepatitis C. US6127384; 2000
   Google Scholar
• Viropharma, Inc. Compounds, compositions and methods for treatment of hepatitis C. US5830905; 1998
   Google Scholar
• Vertex Pharmaceuticals. Preparation of pentacyclic compounds as inhibitors of hepatitis C virus NS3 helicase. Application: WO0024725; 2000
   Google Scholar
• Vertex Pharmaceuticals. Pyrimidine derivative inhibitors of viral helicase.: WO01007027; 2001
   Google Scholar
• Intermune, Inc. Novel inhibitors hepatitis C replication. WO08100867; 2008
   Google Scholar
• Stankiewicz-Drogon A, Palchykovska LG, Kostina VG, et al. New acridone-4-carboxylic acid derivatives as potential inhibitors of Hepatitis C virus infection. Biorg Med Chem 2008;16(19):8846-52
   PubMed Web of Science ®Google Scholar
• Ujjinamatada RK, Baier A, Borowski P, Hosmane RS. An analogue of AICAR with dual inhibitory actibvity against WNV and HCV NTPase/helicase and in vitro screening of 4-carbamoyl-5-(4.6-diamino-2,5-dihydro-1,3,5-triazin-2-yl) inidazole-1-beta-D-ribofuranoside. Bioorg Med Chem Lett 2007;17:2285-8
   PubMed Web of Science ®Google Scholar
• Borowski P, Deinert J, Schalinski S, et al. Halogenated benzimidazoles and benzotraizoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur J Biochem 2003;270:1645-53
   PubMedGoogle Scholar
• Paeshuyse J, Vliegen I, Coelmont L, et al. Comparative in vitro anti-Hepatitis C Virus activities of a selected series of polymerase, protease and helicase inhibitors. Antimicrob Agents Chemother 2008;52(9):3433-7
   PubMed Web of Science ®Google Scholar
• Maga G, Gemma S, Fattorusso C, et al. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleoaside-mimicking inhibitor QU663. Biochemistry 2005;44:9637-44
   PubMed Web of Science ®Google Scholar
• Boguszewska-Chachulska AM, Krawczyk M, Najda A, et al. Searching for a new anti-HCV therapy: Synthesis and properties of tropolone derivatives. Biochem Biophys Res Commun 2006;341(2):641-7
   PubMed Web of Science ®Google Scholar
• Gozdek A, Zhukov I, Polkowska A, et al. NS3 peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. Antimicrob Agents Chemother 2008;52(2):393-401
   PubMed Web of Science ®Google Scholar
• Huang M, Sun Y, Yang W, et al. ACH-806: a potent inhibitor of HCV replication with a novel mechanism of action. J Hepatol 2007;46(Suppl 1):S221
   Google Scholar
• Yang W, Zhao Y, Fabrycki J, et al. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother 2008;52(6):2043-52
   PubMed Web of Science ®Google Scholar
• Achillion Pharmaceuticals. Preparation of substituted aryl thioureas as inhibitors of viral replication. WO04046095; 2004
   Google Scholar
• Achillion Pharmaceuticals. Preparation of substituted (arylacyl)thioureas, their use as antiviral agents, and method for prophylactic or therapeutic treatment of hepatitis C. WO05330284; 2005
   Google Scholar
• Achillion Pharmaceuticals. Preparation of substituted arylthioureas as inhibitors of viral replication. WO05007601; 2005
   Google Scholar
• Achillion Pharmaceuticals. Preparation of azabenzofuran substituted thioureas as inhibitors of viral replication. WO05067900; 2005
   Google Scholar
• Achillion Pharmaceuticals. Preparation of heteroaryl guanidines as inhibitors of Hepatitis C virus replication. WO05095345; 2005
   Google Scholar
• Achillion Pharmaceuticals. Preparation of thiazole compounds for treating Hepatitis C virus infections. WO06122011; 2006
   Google Scholar
• Achillion Pharmaceuticals. Preparation of 2-(phenylamino)thiazole derivatives as inhibitors of viral replication for the treatment of hepatitis C infection. WO07103550; 2007
   Google Scholar
• Wyles DL, Kaihara KA, Schooley RT. synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors. Antimicrob Agents Chemother 2008;52(5):1862-4
   PubMed Web of Science ®Google Scholar
• Viropharma, Inc. Compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and related diseases. WO05051318; 2005
   Google Scholar
• Roberts CD. Inaugural HCV drug discovery conference. LaJolla, California, USA 2008
   Google Scholar
• Sheaffer AK, Lee MS, Chaniewski S, et al. Resistance to a novel HCV replication inhibitor maps to amino acid changes within the NS4B Sequence. 15th International Symposium on Hepatitis C and Related Viruses. San Antonio, Texas USA 2008
   Google Scholar
• Arrow. Company website. 2008 [cited; Available from: www.arrowt.co.uk]
   Google Scholar
• Barnes CM. Abstracts of Papers, 231st American Chemical Society National Meeting. Atlanta, Georgia, USA 2006
   Google Scholar
• Arrow Therapeutics. Pyrazolopyrimidines as anti-hepatitis C agents, their preparation, pharmaceutical compositions and use. WO05047288; 2005
   Google Scholar
• Arrow Therapeutics. Preparation of morpholinylanilino quinazoline derivatives for use as antiviral agents. WO05105761; 2005
   Google Scholar
• Arrow Therapeutics. Preparation of quinazoline derivatives as antiviral agents. WO06079833; 2006
   Google Scholar
• Arrow Therapeutics. Quinazoline derivatives, useful in treating or preventing a flaviviridae infection, processes for preparing them, and pharmaceutical compositions containing them. WO07042782; 2007
   Google Scholar
• Arrow Therapeutics. Preparation of triazolylanilinoquinazolines as antivirals. WO07080401; 2007
   Google Scholar
• Arrow Therapeutics. Preparation of quinazolines as virucides. WO08056149; 2008
   Google Scholar
• Arrow Therapeutics. Biphenyl derivatives and their use in treating hepatitis C. WO07138242; 2007
   Google Scholar
• Najarro P. 14th International Symposium on Hepatitis C Virus and Related Viruses. Glasgow, UK; 2007
   Google Scholar
• XTL. Press release 20th March. 2008 [cited; Available from: www.xtlbio.com]
   Google Scholar
• XTL.14th International Symposium on Hepatitis C Virus and Related Viruses. Glasgow, UK; 2007
   Google Scholar
• Bechtel J. 14th International Symposium on Hepatitis C Virus and Related Viruses. Glasgow, UK; 2007
   Google Scholar
• Genelabs Technologies. N-heterocyclylpyrrolidine carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as antiviral agents. WO07070600; 2007
   Google Scholar
• Genelabs Technologies. Preparation of proline amides for treating Flaviviridae family virus infection. WO07070556; 2007
   Google Scholar
• Genelabs Technologies. Preparation of benzimidazolylpyrrolidinecarboxylates and related compounds as antivirals. WO08070447; 2008
   Google Scholar
• Genelabs Technologies. Preparation of thiazolidine derivatives as antiviral agents. WO08064218; 2008
   Google Scholar
• Bartholomew L. 11th International Symposium on Hepatitis C Virus and Related Viruses. Heidelberg, Germany 2004
   Google Scholar
• Instituto di Researchi di Biologia Moleculare P. Angeletti SpA. Modulators of HCV replication. WO06038039; 2006
   Google Scholar
• Neddermann P, Quintavalle M, Di Pietro C, et al. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol 2004;78(23):13306-14
   PubMed Web of Science ®Google Scholar
• Raboisson P, Lenz O, Lin TI, et al. Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorg Med Chem Lett 2007;17(7):1843-9
   PubMed Web of Science ®Google Scholar
• Tibotec, HCV inhibiting Bi-cyclic pyrimidines. WO06035061; 2006
   Google Scholar
• Tibotec, Fused bicyclic inhibitors of TGFbeta. WO06100310; 2006
   Google Scholar
• Tibotec, Pteridines useful as HCV inhibitors and methods for the preparation thereof. WO06120251; 2006
   Google Scholar
• Bristol-Myers Squibb. Preparation of iminothiazolidinone amino acid derivatives as inhibitors of HCV replication. WO04014852; 2004
   Google Scholar
• Bristol-Myers Squibb. Hepatitis C virus inhibitors. WO08021927; 2008
   Google Scholar
• Bristol-Myers Squibb. Hepatitis C virus inhibitors. WO08021928; 2008
   Google Scholar
• Bristol-Myers Squibb. Hepatitis C virus inhibitors. WO08021936; 2008
   Google Scholar
• Gao M, Fridell R, O'Boyle II, et al. HCV NS5A inhibitors: From Screen Hit to Clinic 15th International Symposium on Hepatitis C Virus & Related Viruses. San Antonio, TX; 2008
   Google Scholar
• Nettles R, Chien C, Chung E, et al. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; 2008
   Google Scholar
• Viropharma Inc. Compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases. WO05051318; 2005
   Google Scholar
• Horscroft N, Lai VC, Cheney W, et al. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir Chem Chemother 2005;16(1):1-12
   PubMedGoogle Scholar